About: Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Sector: Healthcare
Industry: Biotechnology
Latest price: $28.02 (-0.37%)
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
GLPG NASDAQ Galapagos NV ADR
Galapagos NV ADR share price
Atividade de preço de GLPG
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
GLPG price performance
quote.marketSignals